Outcomes of men with HIV and germ cell cancer : Results from an international collaborative study
Hentrich, Marcus Ulrich (Department of Hematology and Oncology. Red Cross Hospital. University of Munich)
Bower, Mark (National Centre for HIV Malignancy. Chelsea and Westminster Hospital)
Daugaard, Gedske (Department of Oncology. University Hospital Copenhagen. Rigshospitalet)
Dieing, Annette (Department of Hematology and Oncology. Vivantes Klinikum am Urban)
Bickel, Markus (Infektiologikum)
Berretta, Massimiliano (Department of Clinical and Experimental Medicine. University of Messina)
Lesmeister, Florian (Department of Hematology and Oncology. Red Cross Hospital. University of Munich)
Jurinovic, Vindi (Institute of Biometrics and Epidemiology. Ludwig Maximilian University of Munich)
Stoehr, Albrecht (Institute for Interdisciplinary Medicine)
Heinzelbecker, Julia (Department of Urology and Pediatric Urology. Saarland University Medical Center and Saarland University)
Krznaric, Ivanka (Practice of Infectious Diseases)
Dieckmann, Klaus-Peter (Department of Urology. Asklepios Klinik Altona)
Necchi, Andrea (IRCCS San Raffaele Hospital and Scientific Institute. Vita-Salute San Raffaele University)
Maroto Rey, Pablo (Institut d'Investigació Biomèdica Sant Pau)
Rockstroh, Jürgen Kurt (Department of Medicine I. University Hospital Bonn)
Brito, Margarida (Instituto Português de Oncologia Francisco Gentil)
Pfister, David (Department of Urology. University Hospital Cologne)
Hoffmann, Christian (University Hospital of Schleswig Holstein)

Data:	2022
Resum:	Background: Previous studies have shown that men with HIV and germ cell cancer (HIV-GCC) have inferior overall survival (OS) in comparison with their HIV-negative counterparts. However, little information is available on treatments and outcomes of HIV-GCC in the era of combination antiretroviral therapy (cART). Methods: This study examined men living with HIV who were 18 years old or older and had a diagnosis of histologically proven germ cell cancer (GCC). The primary outcomes were OS and progression-free survival (PFS). Results: Data for 89 men with a total of 92 HIV-GCCs (2 synchronous GCCs and 1 metachronous bilateral GCC) were analyzed; among them were 64 seminomas (70%) and 28 nonseminomas (30%). The median age was 36 years, the median CD4 T-cell count at GCC diagnosis was 420 cells/µL, and 77% of the patients on cART had an HIV RNA load < 500 copies/mL. Stage I disease was found in 44 of 79 gonadal GCCs (56%). Among 45 cases with primary disseminated GCC, 78%, 18%, and 4% were assigned to the good-, intermediate-, and poor-prognosis groups, respectively, of the International Germ Cell Cancer Collaborative Group. Relapses occurred in 14 patients. Overall, 12 of 89 patients (13%) died. The causes of death were refractory GCC (n = 5), an AIDS-defining illness (n = 3), and other causes (n = 4). After a median follow-up of 6. 5 years, the 5- and 10-year PFS rates were 81% and 73%, respectively, and the 5- and 10-year OS rates were 91% and 85%, respectively. Conclusions: The 5- and 10-year PFS and OS rates of men with HIV-GCC were similar to those reported for men with HIV-negative GCC. Patients with HIV-GCC should be managed identically to HIV-negative patients. Lay Summary: Men living with HIV are at increased risk for germ cell cancer (GCC). Previous studies have shown that the survival of men with HIV-associated germ cell cancer (HIV-GCC) is poorer than the survival of their HIV-negative counterparts. This study examined the characteristics, treatments, and outcomes of 89 men with HIV-GCC in the era of effective combination antiretroviral therapies. The long-term outcomes of men with HIV-GCC were similar to those reported for men with HIV-negative GCC. Patients with HIV-GCC should be managed identically to HIV-negative patients.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Adolescent ; Adult ; AIDS ; Germ cell cancer ; HIV ; HIV-related germ cell cancer ; HIV Infections ; Humans ; Male ; Neoplasm Recurrence, Local ; Neoplasms, Germ Cell and Embryonal ; Nonseminoma ; Seminoma ; Testicular Neoplasms
Publicat a:	Cancer, Vol. 128 Núm. 2 (January 2022) , p. 260-268, ISSN 1097-0142

DOI: 10.1002/cncr.33928
PMID: 34592009

9 p, 203.7 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats